Discovery of AMG 232, a Potent, Selective, and Orally Bioavailable MDM2–p53 Inhibitor in Clinical Development

Cited by (306)

Items 201–300 of 306

1. Fluorine-18 Labeling of the MDM2 Inhibitor RG7388 for PET Imaging: Chemistry and Preliminary Evaluation
   Zhengyuan Zhou, Michael R. Zalutsky, Satish K. Chitneni · 2021 · Molecular Pharmaceutics
2. Thiazolidinones as Potential PGK1 Inhibitors for Treatment of Osteosarcoma Growth and Metastasis
   Xuwen Chen, Meng Li, Zongjing Hu, Donghui Sun, Yikai Xu, Wenwen Dong, Tong Zhu, Weibin Zhang, Shunying Liu · 2025 · Journal of Medicinal Chemistry
3. The Discovery of Potential MDM2 Inhibitors: A Combination of Pharmacophore Modeling, Virtual Screening, Molecular Docking Studies, and in vitro/in vivo Biological Evaluation
   Xuelin Zhang, Chunqiao Zhou, Yang Yang, Hailin Liu, Song Wang, Xiaoli Ding, Wang Hu · 2021 · ChemMedChem
4. Identification of metabolic biomarkers for diagnosis of epithelial ovarian cancer using internal extraction electrospray ionization mass spectrometry (iEESI-MS)
   Jiajia Li, Zhenpeng Wang, Wenjie Liu, Linsheng Tan, Yunhe Yu, Dongzhen Liu, Zhentong Wei, Songling Zhang · 2023 · Cancer Biomarkers
5. Protein–Protein Interaction Inhibitors
   Ian Robert Hardcastle · 2017 · Topics in medicinal chemistry
6. Highly Potent Clickable Probe for Cellular Imaging of MDM2 and Assessing Dynamic Responses to MDM2-p53 Inhibition
   Honorine Lebraud, Richard A. Noble, Nicole Phillips, Keisha Heam, Juan Castro, Yan Zhao, David R. Newell, John Lunec, Stephen R. Wedge, Tom D. Heightman · 2018 · Bioconjugate Chemistry
7. Role of Sex in the Therapeutic Targeting of p53 Circuitry
   Francesca Mancini, Ludovica Giorgini, Emanuela Teveroni, Alfredo Pontecorvi, Fabiola Moretti · 2021 · Frontiers in Oncology
8. Pharmacokinetics and Macrophage Inhibitory Cytokine‐1 Pharmacodynamics of the Murine Double Minute 2 Inhibitor, Navtemadlin (KRT‐232) in Fed and Fasted Healthy Subjects
   Shekman L. Wong, Cecile Marie Krejsa, Dana Lee, Anna L. Harris, Émilie Simard, Xiaohui Wang, Martine Allard, Terry Podoll, Terry E. O’Reilly, J. Greg Slatter · 2022 · Clinical Pharmacology in Drug Development
9. The Clinical and Therapeutic Uses of MDM2 and PSMA and Their Potential Interaction in Aggressive Cancers
   Robyn Bradbury, Wen G. Jiang, Yuxin Cui · 2015 · Biomarkers in Medicine
10. Medicinal applications of spirooxindole and its derivatives
    Mohammad Shahidul Islam, Ved Prakash Verma · 2024 · Elsevier eBooks
11. Functionalization of unsaturated carbon–carbon bonds by continuous-flow ozonolysis
    Caio Massoto Pacheco, Fernanda Alves Lima, Mauro R. B. P. Gomez, Lucas B. Barbosa, Raquel A. C. Leão, Rodrigo O. M. A. de Souza · 2024 · Journal of Flow Chemistry
12. Antineoplastic 4-piperidone-1-phosphonothioates with potential multi-targeted inhibitory properties
    Mohamed S. Bekheit, Siva S. Panda, Benson M. Kariuki, Walid Fayad, Ahmed A. F. Soliman, Hanaa Farag, Adel S. Girgis · 2025 · Scientific Reports
13. POIESIS: a phase III study of add-on navtemadlin in JAK inhibitor-naïve myelofibrosis patients with a suboptimal response to ruxolitinib
    Pankit J. Vachhani, Abdulraheem Yacoub, Raajit K. Rampal, Terrence Bradley, Claire N. Harrison, Tania Jain, Andrew Tucker Kuykendall, Francesca Palandri, John O Mascarenhas, Haifa Kathrin Al‐Ali et al. · 2026 · Future Oncology
14. Elucidation of Conformational Dynamics of MDM2 and Alterations Induced Upon Inhibitor Binding Using Elastic Network Simulations and Molecular Docking
    Nigar Kantarci-Carsibasi · 2021 · Journal of Computational Biophysics and Chemistry
15. Peptide and protein chemistry approaches to study the tumor suppressor protein p53
    Champak Chatterjee, Sumeet K. Singh · 2022 · Organic & Biomolecular Chemistry
16. Recent New Developments in Hofmann, Curtius, Schmidt, Lossen, and Related Reactions
    Masato Matsugi, Takayuki Shioiri · 2023 · Elsevier eBooks
17. Senolytic compounds reduce epigenetic age of blood samples in vitro
    Vithurithra Tharmapalan, Miriam Du Marchie Sarvaas, Michael Bleichert, Martina Wessiepe, Wolfgang Wagner · 2025 · npj Aging
18. Protein-protein interactions at a glance: Protocols for the visualization of biomolecular interactions
    Mariangela Agamennone, Alessandro Nicoli, Sebastian Bayer, Verena Weber, Luca Borro, Shailendra K. Gupta, Marialuigia Fantacuzzi, Antonella Di Pizio · 2021 · Methods in cell biology
19. Management of partial and non‐responding cutaneous squamous cell carcinoma
    Philipp Jansen, Georg Christian Lodde, Klaus Griewank, Eva N. Hadaschik, Alexander Roesch, Selma Ugurel, Lisa Zimmer, Elisabeth Livingstone, Dirk Schadendorf · 2021 · Journal of the European Academy of Dermatology and Venereology
20. Protein–Protein Interaction Inhibitors in Cancer
    Ian Robert Hardcastle · 2016 · Elsevier eBooks
21. Understanding Protein–Protein Interactions: Essential Players in (Patho)physiology (Part 1)
    Andrew John Wilson, Patrick Thomas Gunning · 2016 · ChemBioChem
22. Targeting Protein–Protein Interactions Perspective
    Chun‐wa Chung, Michael M. Hann · 2020 · Wiley eBooks
23. A Perspective on Therapeutic Targeting Against Ubiquitin Ligases to Stabilize Tumor Suppressor Proteins
    Ishaar P. Ganesan, Hiroaki Kiyokawa · 2025 · Cancers
24. Hybrid molecules of ibuprofen and piperidone: a rational approach toward anti-cancer drug development
    Siva S. Panda, Walid Fayad, Ahmed A. F. Soliman, Pablo Shimaoka Chagas, Sahar Emami Naeini, Mohamed Aly Morsy, FaithAnn A Ferguson, Kunj Bihari Gupta, Guido F. Verbeck, Babak Baban et al. · 2025 · Bioorganic & Medicinal Chemistry
25. Copper-Photocatalyzed Selective α-C(sp 3 )-H Sulfonylation of Amides with Sodium Sulfinates via 1,5-Hydrogen Atom Transfer
    Ben Ma, Min Ma, Tianle Zhang, Dong‐Ping Chen, Jingya Yang · 2025 · The Journal of Organic Chemistry
26. Chemical adaptation: bridging synthetic chemistry with drug development
    Ke Ding, Yupeng Li, Yang Zhou, Weixue Huang · 2026 · Science China Life Sciences
27. Intrafamily heterooligomerization as an emerging mechanism of methyltransferase regulation
    Haley V. Hobble, Christine E. Schaner Tooley · 2024 · Epigenetics & Chromatin
28. Discovery of Furopyrimidine‐Pyrazole Hybrid Compounds Targeting p53‐MDM2 Interaction as Anticancer Agents
    Mai A. Mansour, Ghaneya Sayed Hassan, Maiy Y. Jaballah, Rabah A.T. Serya, Necmi Dege, Onur Şahın, Marwa M. Sharaky, Xiaoliang Zhang, Ruixin Su, Kong De et al. · 2025 · Archiv der Pharmazie
29. Discovery of Novel Drug-Conjugate Molecule ZM484 with Dual p53-MDM2 and TOP1 Inhibition for the Treatment of Colorectal Cancer
    Chuanhao Wang, Baobao Chen, Hang Yang, Chengyi Huang, Yanming Zhang, Jianyu Yan, Daozuan Zhang, Anhua Huang, Yuelin Wu, Junwu Zhu et al. · 2025 · Journal of Medicinal Chemistry
30. p53 Drives Lung Cancer Regression through a TSC2/TFEB-dependent Senescence Program
    Mengxiong Wang, Kathryn T. Bieging-Rolett, Alyssa M. Kaiser, Colleen A. Brady, John H. Lockhart, Sofia Ferreira, Kha The Nguyen, Arati Rajeevan, Simone A. Evans, Tianyu Zhao et al. · 2025 · Cancer Discovery
31. Evaluating the FEP+ protocol for predicting binding affinity of congeneric ligands towards various soluble proteins
    S Venkatesh, Arpan Das, Naga Rajiv Lakkaniga · 2025 · RSC Medicinal Chemistry
32. Drug Design Methods to Regulate Protein–Protein Interactions
    Krishna Mohan Poluri, Khushboo Gulati, Deepak Kumar Tripathi, Nupur Nagar · 2023 · Springer eBooks
33. RNF126, 168 and CUL1: The Potential Utilization of Multi-Functional E3 Ubiquitin Ligases in Genome Maintenance for Cancer Therapy
    Hae Ryung Chang · 2023 · Biomedicines
34. Quantitation of navtemadlin in human plasma and brain tissue by liquid chromatography–tandem mass spectrometry
    Amanda B. Kagan, Nicole M. Anders, Avelina Hemingway, Eudocia Q. Lee, Kevin R. Kelly, Hans Chulhee Lee, Meng Xu‐Welliver, Richard Piekarz, Michelle A. Rudek · 2022 · Biomedical Chromatography
35. An Application of Fit Quality to Screen MDM2/p53 Protein-Protein Interaction Inhibitors
    Xin Xue, Gang Bao, Hai-Qing Zhang, Ning-Yi Zhao, Yuan Sun, Yue Zhang, Xiaolong Wang · 2018 · Molecules
36. Design-Rules for Stapled Alpha-Helical Peptides with On-Target In Vivo Activity: Application to Mdm2/X dual antagonists
    Arun Chandramohan, Hubert B. Josien, Tsz Ying Yuen, Ruchia Duggal, Diana Spiegelberg, Lin Yuan Yan, Yu-Chi Angela Juang, Lan Ge, Pietro G. A. Aronica, Kristal Kaan et al. · 2023 · bioRxiv (Cold Spring Harbor Laboratory)
37. E3 ubiquitin ligase components in GtoPdb v.2022.1
    Elena Faccenda, Robert Layfield · 2022 · IUPHAR/BPS Guide to Pharmacology CITE
38. E3 ubiquitin ligase components in GtoPdb v.2022.3
    Elena Faccenda, Robert Layfield · 2022 · IUPHAR/BPS Guide to Pharmacology CITE
39. E3 ubiquitin ligase components in GtoPdb v.2023.2
    Elena Faccenda, Robert Layfield · 2023 · IUPHAR/BPS Guide to Pharmacology CITE
40. Bis-dispiro-indolinone-pyrrolidine-imidazolones with polymethylene linkers between imidazolone fragments
    Vladislav S. Polyakov, E. V. Pervakova, Yuri Konstantinovich Grishin, Elena Kimovna Beloglazkina · 2025 · Tetrahedron Letters
41. p53 mutation-associated prognosis across cancer types underlines hematological malignancy as an applicable cancer type to p53-rescue therapy
    Shujun Xiao, Jiaqi Wu, Kai Wei Tan, Sujiang Zhang, Yuting Dai, Jiarui Wu, Jiale Wu, Xinle Han, Derun Zheng, Xin Wang et al. · 2025 · Fundamental Research
42. Synthesis of bis(dispiro[indolinone-pyrrolidine-imidazolones])
    Vladislav S. Polyakov, E. V. Pervakova, Nikolay V. Zyk, Elena Kimovna Beloglazkina · 2025 · Russian Chemical Bulletin
43. Discovery of AMG 232, a Small Molecule Disrupting the p53-MDM2 Protein–Protein Interaction and Development of a Validation-Ready Process for Its Manufacture
    Seb Caille, Brian S. Lucas · 2022 · ACS symposium series
44. Turizmde Büyük Veri Üzerine Kavramsal Bir Araştırma (2018-2023) (A Conceptual Research on Big Data in Tourism (2018-2023))
    Sadık Serçek, İrfan İLAN · 2023 · Journal of Tourism and Gastronomy Studies
45. Recent Advancements on the Anti-Tumor Small Molecule Inhibitors Targeting the p53-MDM2 Interaction
    涵静 丁 · 2023 · Advances in Clinical Medicine
46. Targeting Hdm2 and Hdm4 in Anticancer Drug Discovery: Implications for Checkpoint Inhibitor Immunotherapy
    Monde McMillan Ntwasa · 2024 · Cells
47. Research Progress on Small Molecule Inhibitors of MDM2-p53 Protein-protein Interaction
    Mei Ying Hu, Chang Xu, Mingxin Xu, Siyu He, Dandan Liu · 2025 · Anti-Cancer Agents in Medicinal Chemistry
48. Computational Studies to Establish the Broad range Potentiality of Violacein- The Anti-Cancerous Drug
    Mary Anupama Palukurty, Swathi Silarapu, Mantriah Tota Pedda · 2017 · IOSR Journal of Biotechnology and Biochemistry
49. Overview of Protein-Protein Interactions and Small-Molecule Inhibitors Under Clinical Development
    Guoqiang Dong, Chunquan Sheng · 2018 · Springer eBooks
50. In Silico Design of MDM2‐Targeting Peptides from a Naturally Occurring Constrained Peptide
    He Ma, Peiju Qiu, Peta J. Harvey, Xiao Li, Zheyu Zhang, Qingliang Xu, Jiazhen Liang, Quentin Kaas, David J. Craik, Jinbo B. Yang et al. · 2019 · ChemMedChem
51. A population pharmacokinetic-pharmacodynamic model of navtemadlin, its glucuronide metabolite (M1) and serum macrophage inhibitory cykokine-1 (MIC-1)
    Lu Zhang, Bill Poland, MICHELLE L. GREEN, Shekman L. Wong, J. Greg Slatter · 2022 · Xenobiotica
52. Enhancing structure-based virtual screening of MDM2–p53 inhibitors: a benchmark of machine learning vs. traditional docking scoring functions
    Marcia Yineth Castillo Tarazona, Gian Pietro Miscione · 2026 · Frontiers in Drug Discovery
53. One‐Carbon Homologation and Homologation–Functionalization Reactions of Aldehydes
    Timothy S. Snowden · 2023
54. Inhibition of the MDM2/p53 Interaction Design, Synthesis and Evaluation of MDM2 Inhibitors
    Mariell Pettersson · 2015 · Gothenburg University Publications Electronic Archive (Gothenburg University)
55. Screening of p53-MDM2 interaction inhibitors through genome editing, high-content screening, and surface plasmon resonance
    Hakan Taşkıran · 2018 · Sabanci University
56. Discovery of AMG 232, a Small Molecule MDM2 Inhibitor in Clinical Development and its Back-up Clinical Candidate, AM-7209
    Yosup Rew, John E. Eksterowicz · 2020 · Royal Society of Chemistry eBooks
57. Cancer Targets Involving the Ubiquitin Proteasome System
    Erika M. V. Araujo · 2021 · Burger's Medicinal Chemistry and Drug Discovery
58. Investigational new drugs against glioblastoma
    David Olayinka. Kamson, Harmon Singh Khela, John Laterra · 2021 · Elsevier eBooks
59. E3 ubiquitin ligase components in GtoPdb v.2021.3
    Elena Faccenda, Robert Layfield · 2021 · IUPHAR/BPS Guide to Pharmacology CITE
60. Discovery of Novel Inhibitors Targeting HDM2: Virtual Screening, Molecular Dynamics Simulation and Binding affinity predication
    Feng Cao, Liang Chen, Feng Xiong, Xingyong Liu, Li Zhang · 2021 · Research Square
61. Targeting MDM2, the antagonist of the tumor suppressor p53
    Anusha Sriraman · 2018
62. Faculty Opinions recommendation of Phase 1 study of the MDM2 inhibitor AMG 232 in patients with advanced P53 wild-type solid tumors or multiple myeloma.
    Richard F. Riedel · 2020 · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature
63. Прогнозування біологічної активності похідних амінометансульфонової кислоти
    П. Б. Антоненко, Р. Е. ХОМА, Yaroslav Rozhkovskyi, В. Й. Кресюн · 2022 · Pharmacology and Drug Toxicology
64. Structure-based Drug Discovery and Advances in Protein Receptor Crystallography
    Miles Congreve, Fiona H. Marshall · 2017 · Royal Society of Chemistry eBooks
65. Research progress in small-molecule modulators of protein-protein interactions
    Bin Yang, Xiangbing Qi · 2023 · Chinese Science Bulletin (Chinese Version)
66. E3 ubiquitin ligase components in GtoPdb v.2023.1
    Elena Faccenda, Robert Layfield · 2023 · IUPHAR/BPS Guide to Pharmacology CITE
67. Synthesis and Mechanism of p53‐MDM2 Inhibitors with Heterocyclic Structures: A Focused Review
    Li‐Tao Ji, Wenjing Zhang, Yi Zhang, Su Zhao, Hai‐Tao Long, Li‐Qing Qin, Jia‐Cheng Tian, Hong‐Zhang Li, Dan‐Xue Zhu, Yan Zhou et al. · 2023 · ChemistrySelect
68. Oncogene inactivation-induced senescence facilitates tumor relapse
    Philipp Schmitt, Katrin Hönig, Maria Teresa Norcia, Marta F. Nogueira, Viktoria Flore, Inés Simó Vesperinas, Maria Villoro-Agud, Lushan Peng, Zuhal Safyürek, Mehreen Tariq et al. · 2026 · Nature Communications
69. Additional file 8 of Ribosomal L1 domain-containing protein 1 coordinates with HDM2 to negatively regulate p53 in human colorectal Cancer cells
    Li Jun Ding, Zhang, Zhiping, Chenhong Zhao, Chen, Lei, Chen, Zhiqiang, Zhang, Jie, Liu, Yaxian, Yesen Nie, He, Yanzhi, Kai Liao et al. · 2021 · Figshare
70. Additional file 3 of Ribosomal L1 domain-containing protein 1 coordinates with HDM2 to negatively regulate p53 in human colorectal Cancer cells
    Li Jun Ding, Zhang, Zhiping, Chenhong Zhao, Chen, Lei, Chen, Zhiqiang, Zhang, Jie, Liu, Yaxian, Yesen Nie, He, Yanzhi, Kai Liao et al. · 2021 · Figshare
71. Additional file 1 of Ribosomal L1 domain-containing protein 1 coordinates with HDM2 to negatively regulate p53 in human colorectal Cancer cells
    Ding, Li, Zhang, Zhiping, Chenhong Zhao, Chen, Lei, Chen, Zhiqiang, Zhang, Jie, Liu, Yaxian, Yesen Nie, He, Yanzhi, Kai Liao et al. · 2021 · Figshare
72. Additional file 7 of Ribosomal L1 domain-containing protein 1 coordinates with HDM2 to negatively regulate p53 in human colorectal Cancer cells
    Li Jun Ding, Zhang, Zhiping, Chenhong Zhao, Chen, Lei, Chen, Zhiqiang, Zhang, Jie, Liu, Yaxian, Yesen Nie, He, Yanzhi, Kai Liao et al. · 2021 · Figshare
73. Additional file 4 of Ribosomal L1 domain-containing protein 1 coordinates with HDM2 to negatively regulate p53 in human colorectal Cancer cells
    Li Jun Ding, Zhang, Zhiping, Chenhong Zhao, Chen, Lei, Chen, Zhiqiang, Zhang, Jie, Liu, Yaxian, Yesen Nie, He, Yanzhi, Kai Liao et al. · 2021 · Figshare
74. Additional file 6 of Ribosomal L1 domain-containing protein 1 coordinates with HDM2 to negatively regulate p53 in human colorectal Cancer cells
    Li Jun Ding, Zhang, Zhiping, Chenhong Zhao, Chen, Lei, Chen, Zhiqiang, Zhang, Jie, Liu, Yaxian, Yesen Nie, He, Yanzhi, Kai Liao et al. · 2021 · Figshare
75. Additional file 5 of Ribosomal L1 domain-containing protein 1 coordinates with HDM2 to negatively regulate p53 in human colorectal Cancer cells
    Li Jun Ding, Zhang, Zhiping, Chenhong Zhao, Chen, Lei, Chen, Zhiqiang, Zhang, Jie, Liu, Yaxian, Yesen Nie, He, Yanzhi, Liao, Kai et al. · 2021 · Figshare
76. Additional file 2 of Ribosomal L1 domain-containing protein 1 coordinates with HDM2 to negatively regulate p53 in human colorectal Cancer cells
    Li Jun Ding, Zhang, Zhiping, Chenhong Zhao, Chen, Lei, Chen, Zhiqiang, Zhang, Jie, Liu, Yaxian, Yesen Nie, He, Yanzhi, Kai Liao et al. · 2021 · Figshare
77. Protein-protein interaction inhibitors in cancer
    Ian Robert Hardcastle, Jennyfer Goujon-Ricci, William Isaac Thompson · 2026 · Elsevier eBooks
78. Innovative Drug and Prodrug Candidates in Cancer Treatment Targeting TP53 Mutations: Challenge and Hope
    Raed M. Al‐Zoubi, Mai Elaarag, Ayman A. Zarour, Khalil Garada, Sally R. Al-Zoubi, Zainab E. Fares, Ahmad Rajeh Al-Qudimat, Mohanad Shkoor, Abbas Khan, Mona A. Sawali et al. · 2026 · Drug Development Research
79. Research Progress on Targeted Therapeutic Strategies for Mutant p53 in Cancer
    开涛 罗 · 2026 · World Journal of Cancer Research
80. Selective modulation of the Protein Kinase CK2 : discovery, syntheses and characterization of non-ATP site inhibitors of CK2
    Benoît Bestgen · 2015
81. The role of NEDD8 pathway in cell invasion and strategies for the use of NEDD8 inhibitors in the clinic
    Lara J. Bou Malhab · 2016 · theses.fr (ABES)
82. MST4 plays dual roles in lung adenocarcinoma by regulating homeostasis of wild-type and mutant p53 protein
    Minghui Zhang, Changwei Hu, Huilong Liu, Chenxi Zhang, Qipeng Shu, Yu-Jian Kang, Yuetian Ding, Jin Zhang, Zhenghui Hu, Haokai Wang et al. · 2026 · Oncogene
83. Navigating the p53‐MDM2 Landscape: Molecular Insights and Therapeutic Strategies
    Mai A. Mansour, Ghaneya Sayed Hassan, Khaled A. M. Abouzid · 2026 · Archiv der Pharmazie
84. Protein–Protein Interactions with the Fragment Molecular Orbital Method
    Dustin C. Woods, Stefania Monteleone, Stéphanie Labouille · 2026 · Methods in molecular biology
85. Imidazole-functionalized cyclotriphosphazene derivatives: Synthesis, biological evaluation and molecular insights into glioblastoma inhibition
    Gülşah Aydın, Arzu Aysan, Ceyda Duyar, Elif Şenkuytu, Merve Dandan Doğancı, Erdinç Doğancı, Derya Davarcı · 2026 · Inorganic Chemistry Communications
86. A Self-Assembled Affibody-Drug Conjugate Nanoagent for EGFR-Targeted Synergistic Codelivery of Exatecan and an MDM2 Inhibitory Peptide
    Mengqiao Zhao, Wenhui Gao, Xuelin Xia, Xiao‐Xia Xia, Zhi‐Gang Qian · 2026 · Molecular Pharmaceutics
87. Hybrid AI-physics screening prioritizes candidate dual MDM2/MDM4 inhibitors from a drug-like library for dedifferentiated liposarcoma
    Solomon Sackitey, Prince Danan Biniyam, Charles Lamptey Mireku, Alberta Hammah, Jesse Ayim Buabeng, Lawrence Kwame Nkrumah, Wise Mawuli Asare, Josephine Frimpomaa Oppong, Emmanuel Gyamfi Obeng, Kwabena Adu-Adjei et al. · 2026 · Research Square
88. Nanopore sensing with machine learning-assisted analysis for real-time single-molecule detection of MDM2-p53TAD interactions
    Jinhyung Kim, Taeyoung Ha, Soyoung Park, Dongwoo Kang, Sunju Lee, Sungwon Lee, Sohee Oh, Minji Chung, Seung‐Wook Chi, Seung Jun Kim et al. · 2026 · Biosensors and Bioelectronics
89. Visible Light‐Mediated Sulfonylation of Enamides: Synthesis of ( E )‐β‐Amidovinyl Sulfones
    Souvik Karmakar, Dhiraj Dutta, Bedanta Sengupta, Parthasarathi Das · 2026 · Chemistry - An Asian Journal
90. Integrated structure-based discovery of indole-enriched putative MDM2-binding hits targeting the p53–MDM2 interface
    Gülşah Aydın, Serdar Durdağı, Mine Yurtsever · 2026 · Journal of Molecular Graphics and Modelling
91. BindingDB Entry 50007839: The past, present and future of potential small-molecule drugs targeting p53-MDM2/MDMX for cancer therapy.
    BindingDB · 2021 · UC San Diego
92. BindingDB Entry 50010808: Medicinal Chemistry of Inhibiting RING-Type E3 Ubiquitin Ligases.
    BindingDB · 2021 · UC San Diego
93. BindingDB Entry 50045594: Small-molecule inhibitors of the MDM2-p53 protein-protein interaction (MDM2 Inhibitors) in clinical trials for cancer treatment.
    BindingDB · 2016 · UC San Diego
94. BindingDB Entry 50003121: Role of p53 circuitry in tumorigenesis: A brief review.
    BindingDB · 2020 · UC San Diego
95. BindingDB Entry 50003153: The development of piperidinones as potent MDM2-P53 protein-protein interaction inhibitors for cancer therapy.
    BindingDB · 2020 · UC San Diego
96. BindingDB Entry 50014421: Development of MDM2 degraders based on ligands derived from Ugi reactions: Lessons and discoveries.
    BindingDB · 2022 · UC San Diego
97. BindingDB Entry 50049265: Discovery of 4-((3'R,4'S,5'R)-6¿-Chloro-4'-(3-chloro-2-fluorophenyl)-1'-ethyl-2¿-oxodispiro[cyclohexane-1,2'-pyrrolidine-3',3¿-indoline]-5'-carboxamido)bicyclo[2.2.2]octane-1-carboxylic Acid (AA-115/APG-115): A Potent and Orally Active Murine Double Minute 2 (MDM2) Inhibitor in Clinical Deve
    BindingDB · 2019 · UC San Diego
98. BindingDB Entry 50045593: Discovery of AM-7209, a potent and selective 4-amidobenzoic acid inhibitor of the MDM2-p53 interaction.
    BindingDB · 2016 · UC San Diego
99. BindingDB Entry 50006473: New Frontiers in Druggability.
    BindingDB · 2020 · UC San Diego
100. BindingDB Entry 50000810: Design, synthesis and biological evaluation of novel antitumor spirotetrahydrothiopyran-oxindole derivatives as potent p53-MDM2 inhibitors.
     BindingDB · 2020 · UC San Diego